(24/7 MARKET NEWS) – IMV Inc. (Nasdaq: IMV) announced, this morning, positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment. Further result details will be presented February 7-10, 2023, in a podium presentation at the Immuno-Oncology 360° conference, in New York City.
IMV is trading higher in this morning’s premarket, at $2.85, up $0.66 (+30.40%), on 150 thousand shares traded.
Its 52-week range is $2.0336 to $15.30. Its next inflection points are $3.23 and $3.40, but they’re not on big volume, so this is a favorable setup for a potential big move.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
